MX2016007716A - Metodos para el tratamiento de trastornos cerebrales o la identificacion de biomarcadores relacionados con estos. - Google Patents

Metodos para el tratamiento de trastornos cerebrales o la identificacion de biomarcadores relacionados con estos.

Info

Publication number
MX2016007716A
MX2016007716A MX2016007716A MX2016007716A MX2016007716A MX 2016007716 A MX2016007716 A MX 2016007716A MX 2016007716 A MX2016007716 A MX 2016007716A MX 2016007716 A MX2016007716 A MX 2016007716A MX 2016007716 A MX2016007716 A MX 2016007716A
Authority
MX
Mexico
Prior art keywords
brain disorders
treating brain
biomarkers related
biomarkers
treating
Prior art date
Application number
MX2016007716A
Other languages
English (en)
Spanish (es)
Inventor
Moskal Joseph
Original Assignee
Univ Northwestern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Northwestern filed Critical Univ Northwestern
Publication of MX2016007716A publication Critical patent/MX2016007716A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
    • A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Physics & Mathematics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
MX2016007716A 2013-12-13 2014-12-15 Metodos para el tratamiento de trastornos cerebrales o la identificacion de biomarcadores relacionados con estos. MX2016007716A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361915835P 2013-12-13 2013-12-13
PCT/US2014/070340 WO2015089503A2 (en) 2013-12-13 2014-12-15 Methods of treating brain disorders or identifying biomarkers related thereto

Publications (1)

Publication Number Publication Date
MX2016007716A true MX2016007716A (es) 2017-03-31

Family

ID=53371976

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016007716A MX2016007716A (es) 2013-12-13 2014-12-15 Metodos para el tratamiento de trastornos cerebrales o la identificacion de biomarcadores relacionados con estos.

Country Status (9)

Country Link
US (1) US20160345855A1 (enExample)
EP (2) EP3721799A1 (enExample)
JP (2) JP2017500306A (enExample)
CN (2) CN106102762A (enExample)
AU (2) AU2014361822A1 (enExample)
CA (1) CA2933372A1 (enExample)
IL (2) IL246148A0 (enExample)
MX (1) MX2016007716A (enExample)
WO (1) WO2015089503A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3362080A1 (en) * 2015-10-16 2018-08-22 Northwestern University Pharmaceutical combination of an atypical antipsychotic and an nmda modulator for the treatment of schizophrenia,bipolar disorder, cognitive impairment and major depressive disorder
CN113557028A (zh) * 2019-01-11 2021-10-26 诺雷克斯股份有限公司 雷帕替奈的盐和晶型
CN110123342B (zh) * 2019-04-17 2021-06-08 西北大学 一种基于脑电波的网瘾检测方法及系统

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
US20050273017A1 (en) * 2004-03-26 2005-12-08 Evian Gordon Collective brain measurement system and method
WO2007123799A2 (en) * 2006-04-03 2007-11-01 The Trustees Of The University Of Pennsylvania Assessing subject's reactivity to psychological stress using fmri
CA2659099A1 (en) * 2006-06-15 2007-12-21 Mars, Incorporated Use of cocoa flavanols and procyanidins to improve executive cognitive and cerebral blood flow
US8951968B2 (en) * 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
HRP20140784T1 (hr) * 2009-10-05 2014-10-10 Northwestern University Glyx-13 za uporabu u postupku tretiranja refraktornih depresija
BR112013027554A2 (pt) * 2011-04-27 2016-09-06 Univ Northwestern "usos de compostos no tratamento de mal de alzheimer, doença de huntington, autismo e outros distúrbios"
JP2015505314A (ja) * 2012-01-09 2015-02-19 武田薬品工業株式会社 アルツハイマー病を治療する方法及び医薬品

Also Published As

Publication number Publication date
EP3079579A2 (en) 2016-10-19
AU2019264583A1 (en) 2019-12-05
JP2020007333A (ja) 2020-01-16
WO2015089503A3 (en) 2015-10-01
EP3721799A1 (en) 2020-10-14
CN106102762A (zh) 2016-11-09
US20160345855A1 (en) 2016-12-01
JP2017500306A (ja) 2017-01-05
EP3079579A4 (en) 2017-07-19
IL276431A (en) 2020-09-30
IL246148A0 (en) 2016-07-31
AU2014361822A1 (en) 2016-07-28
CA2933372A1 (en) 2015-06-18
CN111920412A (zh) 2020-11-13
WO2015089503A2 (en) 2015-06-18

Similar Documents

Publication Publication Date Title
IL244709A0 (en) Methods for diagnosis and treatment of eosinophilic disorders
IN2015DN00438A (enExample)
MD20160024A2 (ro) Modularea imunităţii tumorale
SG11201601412XA (en) Compositions and methods for the treatment of presbyopia
ZA201601024B (en) Methods and compositions for treating brain diseases
PL3046470T3 (pl) Diagnozowanie i leczenie zaburzeń ruchu
IL239957A0 (en) Assessment, testing and treatment of pkal mediated disorders
IL239428A0 (en) Evaluation and treatment of bradykinin-mediated disorders
IN2014DN05885A (enExample)
PH12015501071A1 (en) Combination therapy of anti-her3 antibodies
MX2016003002A (es) Metodos para determinar la respuesta a la terapia.
MX2016015163A (es) Biomarcadores mit y metodos para su uso.
PH12016500598A1 (en) Protoxin-ii variants and methods of use
AU352731S (en) Safety apparatus
IL276431A (en) Treatment of the brain disorders and related symptoms
ZA201506705B (en) Methods of treating dyskinesia and related disorders
EP3189070A4 (en) Novel compounds and methods of treating or ameliorating an il-1r-mediated disease or disorder using same
EP3008211A4 (en) METHOD AND KITS FOR TREATMENT AND CLASSIFICATION OF PERSONS WITHOUT THE RISK OF AN EXISTING OR EXISTING TRAP1 FUNCTIONAL CHANGE
SG10201802808SA (en) Method of treating ocular disorders
EP3008180A4 (en) METHOD AND KITS FOR TREATMENT AND CLASSIFICATION OF PERSONS
ZA201503834B (en) Identifying subjects in need of treatment
AU352100S (en) Electrical apparatus
AU352101S (en) Electrical apparatus
AU2014353098A8 (en) Methods of treating allergies and autoimmune diseases with homogenate of axenic c. eleganis
AU351339S (en) Gemstone